Navigation Links
Comparing Psoriasis Treatments

A new study shows two common treatments for psoriasis -- methotrexate and cyclosporine -- are equally effective in relieving symptoms of the disease. //

Researchers in Amsterdam studied nearly 90 patients with moderate-to-severe psoriasis. Half of the patients were given methotrexate, and the other half were treated with cyclosporine. Researchers evaluated the side effects and effectiveness of each drug. They also recorded the time patients were in remission and assessed their quality of life. None of the participants had previously been treated with methotrexate or cyclosporine.

Results of the study show the overall response rate for both drugs was more than 90 percent. Seventeen patients in the methotrexate group and 14 patients in the cyclosporine group reached nearly complete remission. Twenty-six patients in the methotrexate group and 30 patients in the cyclosporine group achieved partial remission. However, after 16 weeks of treatment, no significant difference in overall effectiveness was seen between the two groups.

More than 100 patients in the methotrexate group and more than 150 patients in the cyclosporine group reported side effects. More patients in the methotrexate group reported nausea, and patients in the cyclosporine group were more likely to report headaches. There were no significant reported differences in quality of life between the two groups.

Authors of the study say the overall effectiveness of methotrexate is similar to that of cyclosporine. They conclude, "Differences between the treatments in terms of side effects, long-term adverse effects, ease of administration, and costs can be used to guide treatment decisions in individual cases."
'"/>




Page: 1

Related medicine news :

1. Comparing Breast surgery techniques
2. Comparing heart disease treatments
3. New and unique treatment for Psoriasis patients
4. Psoriasis Increases Cancer Risk
5. Help for Psoriasis
6. Managing Patients With Psoriasis
7. Effective Treatment Option For Psoriasis
8. Smoking Aggravates Psoriasis
9. Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder
10. Short-Term Topical Corticosteroid May Offer Relief for Certain Type of Psoriasis
11. Psoriasis raises risk for heart attack
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: